Intramuscular delivery of mRNA-encoded single-chain variable fragments prevents myotoxin II-induced skeletal muscle damage in a preclinical model
Trends in Biotechnology · 2026
DOI: 10.1016/j.tibtech.2025.10.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2026. Verfasst von José R Almeida und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Reading, Reading, UK; Biomolecules Discovery Group, Universidad Regional Amazónica Ikiam, Km 7 Via Muyuna, Tena, Ec…. Hauptthemen laut MEDLINE: RNA, Messenger, Muscle, Skeletal, Single-Chain Antibodies, Crotalid Venoms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, European Research Council, Medical Research Council.
Abstract (Originalsprache)
Antivenom is the only effective treatment for snakebites, but it often fails to tackle venom-induced local tissue/muscle damage, leading to permanent disabilities. We investigated whether monoclonal single-chain variable fragments (scFvs) targeting myotoxin II (M-II) from Bothrops asper venom, delivered via mRNA-lipid nanoparticles (LNPs), could neutralise M-II-induced adverse effects under diverse settings. Human cultured myotubes transfected with mRNA-LNPs expressed scFvs within 24 h and showed resistance to both M-II and venom. In a mouse model, a single intramuscular injection of mRNA-LNPs prompted scFv expression within 48 h and protected against M-II-induced damage. This approach reduced biomarkers for muscle injury, myonecrosis, and damage to the basement membrane and vasculature. This study demonstrates the use of mRNA technology in snakebite management, serving as a proof of concept to improve treatments for envenomings. Although a prophylactic approach may not be feasible for snakebites, prompt delivery of antibodies at the bite site might improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Reading, Reading, UK; Biomolecules Discovery Group, Universidad Regional Amazónica Ikiam, Km 7 Via Muyuna, Tena, Ecuador.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
- School of Pharmacy, University of Reading, Reading, UK.
- School of Biological Sciences, University of Reading, Reading, UK.
- Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
- Instituto Clodomiro Picado, Facultad de Microbiologia, Universidad de Costa Rica, San José, Costa Rica.
Förderung
- Wellcome Trust
- European Research Council
- Medical Research Council
- Villum Foundation
- H2020 Marie Skłodowska-Curie Actions
- FP7 Ideas: European Research Council
- UK Research and Innovation Medical Research Council
- Wellcome
Zitieren
APA
Almeida, J. R., Sørensen, C. V., Gilabadi, S., Williams, J., Haidar, H. B., von Bülow Møiniche, M., Benard-Valle, M., Rivera-de-Torre, E., Schultz, D., Urquhart, A., Lomonte, B., Patel, K., Laustsen, A. H., & Vaiyapuri, S. (2026). Intramuscular delivery of mRNA-encoded single-chain variable fragments prevents myotoxin II-induced skeletal muscle damage in a preclinical model. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2025.10.017
Vancouver
Almeida JR, Sørensen CV, Gilabadi S, Williams J, Haidar HB, von Bülow Møiniche M, et al. Intramuscular delivery of mRNA-encoded single-chain variable fragments prevents myotoxin II-induced skeletal muscle damage in a preclinical model. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2025.10.017
BibTeX
@article{Almeida2026,
author = {Almeida, José R and Sørensen, Christoffer V and Gilabadi, Soheil and Williams, Jarred and Haidar, Husain Bin and von Bülow Møiniche, Mark and Benard-Valle, Melisa and Rivera-de-Torre, Esperanza and Schultz, David and Urquhart, Andrew and Lomonte, Bruno and Patel, Ketan and Laustsen, Andreas H and Vaiyapuri, Sakthivel},
title = {Intramuscular delivery of mRNA-encoded single-chain variable fragments prevents myotoxin II-induced skeletal muscle damage in a preclinical model},
journal = {Trends in Biotechnology},
year = {2026},
doi = {10.1016/j.tibtech.2025.10.017}
}
EUVIMED